Demographics, laboratory and clinical characteristics of participants
| Controls (n=44) | pSS (n=69) | |
|---|---|---|
| Demographic characteristics | ||
| Female, n (%) | 40/44 (91) | 62/69 (90) |
| Mean age (years) | 51±15 | 58±13 |
| Disease duration (years) | – | 10.8±7.7 |
| 2002 American–European criteria | – | 4.2±0.4 |
| Sjögren manifestations, n (%) | ||
| Ocular symptoms | – | 69/69 (100) |
| Oral symptoms | – | 66/69 (96) |
| Positive ocular tests | – | 53/69 (77) |
| Positive histopathology | – | 39/69 (57) |
| Positive salivary gland tests | – | 2/69 (3) |
| Anti-SSA | – | 58/69 (84) |
| Anti-Ro52 | – | 54/56 (96) |
| Anti-Ro60 | – | 47/56 (84) |
| Anti-SSB | – | 38/69 (55) |
2002 American–European criteria: number of criteria fulfilled out of the six criteria items.
Positive histopathology: focus score ≥1, defined as a number of lymphocytic foci containing more than 50 lymphocytes per 4 mm2.
Positive salivary gland tests: sialography showing the presence of diffuse sialectasias or salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer.
pSS, primary Sjögren's syndrome.